DURECT Corporation Down Nearly 20% Pre-Market on FDA Rejection

by Benzinga Staff
June 24, 2011 7:24 AM | 10 seconds read |
DURECT Corporation DRRX is down nearly 20% pre-market after FDA rejected a drug that the company partially responsible for. The company is trading at $2.49 in pre-market.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Pre-Market OutlookHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!